Andere talen COMPASS Pathways plc

Aandelen

CMPS

US20451W1018

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,04 ^USD	+0,83%		-3,21%	-30,97%

26/06	Compass Pathways plc benoemt Lori Englebert tot Chief Commercial Officer, met ingang van 8 juli 2024	CI
05/06	COMPASS PATHWAYS PLC : Morgan Stanley herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Compass Pathways appoints Lori Englebert as Chief Commercial Officer	26/06
Compass Pathways plc Appoints Lori Englebert as Chief Commercial Officer, Effective July 8, 2024	26/06
FDA panel to review psychedelic drug MDMA for first time	04/06
Clarify Pharma confirms name change to File Forge	22/05
COMPASS Pathways : 2024 AGM Voting Results	13/05
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights	08/05
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder	08/05
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder	08/05
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment	02/05
Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression	29/04
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression	29/04
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	18/04
Compass Pathways Insider Sold Shares Worth $597,964, According to a Recent SEC Filing	18/04
Clarify Pharma to change name to File Forge Technology	17/04
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	02/04
Compass Pathways Insider Sold Shares Worth $461,332, According to a Recent SEC Filing	02/04
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	01/04
Compass Pathways Insider Sold Shares Worth $445,552, According to a Recent SEC Filing	01/04
ADRs End Lower; NuCana Slides 15%	28/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen COMPASS Pathways plc

Aandelen

CMPS

US20451W1018

Andere talen

Filters